nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.12.2012 | Original article

Radiotherapy after radical prostatectomy: immediate or early delayed?

verfasst von: Dr. med. D. Bottke, D. Bartkowiak, M. Schrader, T. Wiegel

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Biochemical recurrence after radical prostatectomy (RP) is associated with risk indicators, including Gleason score, preoperative PSA level, tumor stage, seminal vesicle invasion, and positive surgical margins. The 5-year biochemical progression rate among predisposed patients is as high as 50–70%. Post-RP treatment options include adjuvant radiotherapy (ART, for men with undetectable PSA) or salvage radiotherapy (SRT, for PSA persisting or re-rising above detection threshold). Presently, there are no published randomized trials evaluating ART vs. SRT directly.

Methods

Published data on ART and SRT were reviewed to allow a comparison of the two treatment approaches.

Results

Three randomized phase III trials demonstrated an almost 20% absolute benefit for biochemical progression-free survival after ART (60–64 Gy) compared to a “wait and see” policy. The greatest benefit was achieved in patients with positive margins and pT3 tumors.

SRT can be offered to patients with elevated PSA after RP. In 30–70% of SRT patients, PSA will decrease to an undetectable level, thus giving a second curative chance. The rate of side effects for both treatments is comparably low.

The role of irradiation of pelvic lymph nodes and the additional use of hormone therapy and radiation dose are discussed.

Conclusion

It remains unclear whether early SRT initiated after PSA failure is equivalent to ART. Where SRT is indicated, it should be started as early as possible.

Anscher MS, Clough R, Dodge R (2000) Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48:369–375PubMedCrossRef

Begg CB, Riedel ER, Bach PB et al (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138–1144PubMedCrossRef

Bernard JR Jr, Buskirk SJ, Heckman MG et al (2010) Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 76:735–740PubMedCrossRef

Bolla M, Reijke TM de, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527PubMedCrossRef

Bolla M, Poppel H van, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578PubMedCrossRef

Bolla M, Van Poppel H, Tombal B et al (2010) 10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911). Int J Radiat Oncol Biol Phys 78:S 29CrossRef

Bottke D, Abrahamsson PA, Welte B et al (2007) Adjuvant radiotherapy after radical prostatectomy. EJC (Suppl) 5:171–176

Briganti A, Karnes RJ, Pozzo LF et al (2011) Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59:832–840PubMedCrossRef

Budiharto T, Perneel C, Haustermans K et al (2010) A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 97:474–479PubMedCrossRef

10.

Buskirk SJ, Pisansky TM, Schild SE et al (2006) Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176:985–990PubMedCrossRef

11.

Cadeddu JA, Partin AW, DeWeese TL et al (1998) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159:173–177, (discussion 7–8)PubMedCrossRef

12.

Choo R, Danjoux C, Gardner S et al (2009) Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys 75:983–989PubMedCrossRef

13.

Chun FK, Graefen M, Zacharias M et al (2006) Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24:273–280PubMedCrossRef

14.

Cimitan M, Bortolus R, Morassut S, et al (2006) [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387–1398PubMedCrossRef

15.

Coen JJ, Zietman AL, Thakral H et al (2002) Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20:3199–3205PubMedCrossRef

16.

Connolly JA, Shinohara K, Presti JC Jr et al (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225–231PubMedCrossRef

17.

Da Pozzo LF, Cozzarini C, Briganti A et al (2009) Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55:1003–1111CrossRef

18.

Deliveliotis C, Manousakas T, Chrisofos M et al (2007) Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 25:309–313PubMedCrossRef

19.

Do T, Parker RG, Do C et al (1998) Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4:324–330PubMed

20.

Garg MK, Tekyi-Mensah S, Bolton S et al (1998) Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51:998–1002PubMedCrossRef

21.

Hagan M, Zlotecki R, Medina C et al (2004) Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59:329–340PubMedCrossRef

22.

Hanlon AL, Horwitz EM, Hanks GE et al (2004) Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 58:43–52PubMedCrossRef

23.

Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef

24.

Horwitz EM, Bae K, Hanks GE et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497–2504PubMedCrossRef

25.

Kaminski JM, Hanlon AL, Joon DL et al (2003) Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 57:24–28PubMedCrossRef

26.

King CR, Kapp DS (2008) Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71:346–350PubMedCrossRef

27.

Loeb S, Roehl KA, Viprakasit DP et al (2008) Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol 54:88–94PubMedCrossRef

28.

Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy fpr prostate cancer. Int J Radiat Oncol Biol Phys 76:361–368PubMedCrossRef

29.

Miralbell R, Vees H, Lozano J et al (2007) Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67:356–361PubMedCrossRef

30.

Neuhof D, Hentschel T, Bischof M et al (2007) Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 67:1411–1417PubMedCrossRef

31.

Ost P, De Troyer B, Fonteyne V et al (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:1316–1322PubMedCrossRef

32.

Parker C, Sydes MR, Catton C et al (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99:1376–1379PubMedCrossRef

33.

Pazona JF, Han M, Hawkins SA et al (2005) Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174:1282–1286PubMedCrossRef

34.

Picchio M, Briganti A, Fanti S et al (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59:51–60PubMedCrossRef

35.

Pinto F, Prayer-Galetti T, Gardiman M et al (2006) Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol Int 76:202–208PubMedCrossRef

36.

Pisansky TM, Kozelsky TF, Myers RP et al (2000) Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163:845–850PubMedCrossRef

37.

Poortmans P, Bossi A, Vandeputte K et al (2007) Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84:121–127PubMedCrossRef

38.

Rinnab L, Mottaghy FM, Blumstein NM et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786–793PubMedCrossRef

39.

Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914PubMedCrossRef

40.

Roscigno M, Cozzarini C, Scattoni V et al (2007) A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiother Oncol 82:30–37PubMedCrossRef

41.

Rossi CJ Jr, Joe Hsu IC, Abdel-Wahab M et al (2011) ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer. Am J Clin Oncol 34:92–98PubMedCrossRef

42.

Salomon L, Anastasiadis AG, Antiphon P et al (2003) Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int 70:291–296PubMedCrossRef

43.

Scattoni V, Picchio M, Suardi N et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52:423–429PubMedCrossRef

44.

Scattoni V, Roscigno M, Raber M et al (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44:407–414PubMedCrossRef

45.

Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385PubMedCrossRef

46.

Shekarriz B, Upadhyay J, Wood DP Jr et al (1999) Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 54:1044–1048PubMedCrossRef

47.

Shipley WU, Hunt D, Lukka H et al (2010) Initial Report of RTOG 9601: a phase III trial in prostate cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following Radical Prostatectomy (RP) with pT2–3, N0 disease, and elevated PSA levels. Int J Radiat Oncol Biol Phys 78:S 27CrossRef

48.

Siegmann A, Bottke D, Faehndrich J et al (2012) Salvage radiotherapy after prostatectomy—What is the best time to treat? Radiother Oncol: 103:239–243

49.

Siegmann A, Bottke D, Faehndrich J et al (2011) Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 187:467–472PubMedCrossRef

50.

Soto DE, Passarelli MN, Daignault S et al (2011) Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys

51.

Spiotto MT, Hancock SL, King CR (2007) Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69:54–61PubMedCrossRef

52.

Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916PubMedCrossRef

53.

Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041PubMedCrossRef

54.

Stephenson AJ, Shariat SF, Zelefsky MJ et al (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325–1332PubMedCrossRef

55.

Stephenson AJ, Wood DP, Kattan MW et al (2009) Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 182:1357–1263PubMedCrossRef

56.

Swindle P, Eastham JA, Ohori M et al (2005) Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174:903–907PubMedCrossRef

57.

Thompson IM Jr, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329–2335PubMedCrossRef

58.

Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962PubMedCrossRef

59.

Trabulsi EJ, Valicenti RK, Hanlon AL et al (2008) A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3–4N0 prostate cancer. Urology 72:1298–1302, (discussion 302–304)PubMedCrossRef

60.

Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769PubMedCrossRef

61.

Tsien C, Griffith KA, Sandler HM et al (2003) Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology 62:93–98PubMedCrossRef

62.

Van der Kwast TH, Bolla M, Van Poppel H et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186CrossRef

63.

Ward JF, Zincke H, Bergstralh EJ et al (2004) Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172:2244–2248PubMedCrossRef

64.

Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef

65.

Wiegel T, Lohm G, Bottke D et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome—results of a retrospective study. Int J Radiat Oncol Biol Phys 73:1009–1016PubMedCrossRef

66.

Wiltshire KL, Brock KK, Haider MA et al (2007) Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 69:1090–1099PubMedCrossRef

Titel: Radiotherapy after radical prostatectomy: immediate or early delayed?
verfasst von: Dr. med. D. Bottke
D. Bartkowiak
M. Schrader
T. Wiegel
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 12/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0234-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Radiotherapy after radical prostatectomy: immediate or early delayed?

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function

When are breast cancer patients old enough for the quitclaim of local control?

Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer

Prognostic factors and a survival score for patients with metastatic spinal cord compression from colorectal cancer

Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer

Expander/implant breast reconstruction before radiotherapy

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie